
This study investigates the impact of 52 weeks of recombinant human growth hormone (rhGH) treatment on sleep-related breathing disorders (SRBDs) in toddlers with Prader–Willi syndrome (PWS). Seventeen PWS patients receiving rhGH treatment were compared with 17 age-matched controls. Results revealed that rhGH administration did not adversely affect various respiratory and sleep parameters, including obstructive apnea–hypopnea index and oxygen saturation. Additionally, increased levels of insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) associated with rhGH treatment did not worsen SRBDs. The findings suggest that early initiation of rhGH therapy in PWS toddlers is not deleterious to SRBDs.
Like
Save
Share